Concepedia

Michael I. Jesson

MI

Statistics

Publications

17

Citations

2.1K

H-Index

15

Active since

1987

Affiliations

Pfizer (United States)(Current)

Kyushu University

University of Manitoba

Michael I. Jesson is an author at Pfizer (United States) specializing in pharmacology, medicine, and immunology.

ORCID

Publications per year

1987–2019

17

Publications

17

Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

Kamran Ghoreschi, Michael I. Jesson, Li Xiong et al. · The Journal of Immunology · 2011 · 644 citations · Full text

, , +17

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

Debra M. Meyer, Michael I. Jesson, Xiong Li et al. · Journal of Inflammation · 2010 · 459 citations · Full text

, , +17

PT-100, a Small Molecule Dipeptidyl Peptidase Inhibitor, Has Potent Antitumor Effects and Augments Antibody-Mediated Cytotoxicity via a Novel Immune Mechanism

Sharlene Adams, Glenn T. Miller, Michael I. Jesson et al. · Cancer Research · 2004 · 200 citations

, , +17

PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor

Hua Xu, Michael I. Jesson, Uthpala Seneviratne et al. · ACS Chemical Biology · 2019 · 161 citations

, , +15

JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production

Timothy P. LaBranche, Michael I. Jesson, Chad Storer et al. · Arthritis & Rheumatism · 2012 · 136 citations

, , +17

1–5 of 17